Currently Viewing:
Newsroom
Currently Reading
Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment
February 25, 2018 – Kaitlynn Ely
Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes
February 24, 2018 – Samantha DiGrande
Current Risk-Adjustment Approach Underpaid Insurance Carriers for Part-Year Members
February 24, 2018 – Kaitlynn Ely
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 23, 2018 – Jaime Rosenberg
Survey Examines Whether Primary Care Doctors Gave Correct ADHD Diagnosis
February 23, 2018 – Allison Inserro
This Week in Managed Care: February 23, 2018
February 23, 2018
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
February 23, 2018 – Kelly Davio
Hydroxychloroquine Ineffective in Treating Hand Osteoarthritis Compared With Placebo
February 23, 2018 – Kaitlyn Ely
AJMC® in the Press, February 23, 2018
February 23, 2018 – AJMC Staff

Sanofi Says Toujeo Met Objective in Head-to-Head Insulin Study

Mary Caffrey
Sanofi’s newest insulin met its primary objective in a large head-to-head trial that compared it with its chief competitor.
Sanofi’s newest insulin, Toujeo, met its primary objective in a large head-to-head trial that compared it with its chief competitor, Novo Nordisk’s Tresiba, according to a statement from Sanofi released Monday.

The BRIGHT study compared insulin glargine 300 units/mL (Toujeo) with insulin degludec (Tresiba), in patients with type 2 diabetes who had uncontrolled glycated hemoglobin (A1C) while taking oral glucose-controlling therapies, with or without a glucagon-like peptide-1 (GLP-1) receptor agonist. The study followed 929 adults with uncontrolled T2D.

Full results of the BRIGHT study will be presented in 2018, the statement said.

In the study, the primary objective was to determine if the effect of Toujeo on A1C was similar to Tresiba, according to the statement from Sanofi. Secondary objective included the share of patients who experience adverse events, the number of patients who experience hypoglycemia during the study, and the rate of hypoglycemic events.

Researchers also asked patients about their use of rescue therapy and recorded patient-reported outcomes using the Diabetes Treatment Satisfaction Questionnaire and the Hypoglycemic Attitudes and Behavior Scale.

The study comes amid a movement with the diabetes research and advocacy community to work with FDA to use clinical measures besides A1C in the approval process, with the possibility that these measures might be incorporated into a product label. A recent paper published in Diabetes Care calls for consideration to be given to the ability of drugs and devices to prevent hypoglycemia, to improve time in range and to prevent diabetic ketoacidosis.

“The most recently introduced long-acting insulins have already demonstrated significant blood glucose lowering benefit to adult patients with diabetes,” said Riccardo Perfetti, head of Global Diabetes Medical Team, ‎Sanofi, in the statement. "From the perspective of physicians and patients, hypoglycemia remains a major limiting factor in effective blood sugar management in diabetes. We believe that these first comparative clinical data assessing similarity and difference not only in efficacy, but also in the important safety aspect, such as low blood sugar events, can support physicians in their treatment decisions. We look forward to release of the full results of the study.”

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!